Project Details
Description
This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive one dose of recombinant COVID-19 vaccine sequentially at different schedules of 1-3 months, 3-6 months and ≥ 6 months after two doses of vaccination, and the subjects vaccinated at different schedules will be randomly assigned to different sequential immunization groups. At the same time, each sequential immunization group will be matched with a control group with the inactivated COVID-19 vaccine (vero cells) as the booster dose.
| Status | Finished |
|---|---|
| Effective start/end date | 12/09/21 → 31/01/24 |
Collaborative partners
- National Vaccine and Serum Institute (NVSI) (lead)
- China National Biotec Group Company Limited
- Lanzhou Institute of Biological Products Co., Ltd.
- Sheikh Khalifa Medical City
Keywords
- COVID-19
- Pneumonia, Viral
- Pneumonia
- Respiratory Tract Infections
- Infections
- Virus Diseases
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Lung Diseases
- Respiratory Tract Diseases
- Coronavirus Infections
- Immunologic Factors
- Physiological Effects of Drugs
- Vaccines
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.